Literature DB >> 23732156

Response and non-response to renal denervation: who is the ideal candidate?

Christian Ukena1, Bodo Cremers, Sebastian Ewen, Michael Böhm, Felix Mahfoud.   

Abstract

Catheter-based renal denervation (RDN) leads to a considerable decrease of blood pressure in the vast majority of patients with resistant hypertension. However, only minor or no blood pressure change is achieved in some patients. This non-reponse is defined as a reduction of office systolic blood pressure of less than 10 mmHg following RDN. The rates of non-response vary between 8-37%. Here several causes are discussed such as inappropriate patient selection, an ineffective procedure, the subordinate contribution of sympathetic activation for the maintenance of hypertension, and patient conditions such as non-adherence to drug therapy. Based on current evidence, an ideal candidate for RDN has high baseline blood pressure, which is known to be the best predictor for blood pressure reduction after RDN. In order to ensure treatment success further criteria have to be fulfilled, such as exclusion of secondary hypertension and optimised medical therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23732156     DOI: 10.4244/EIJV9SRA10

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  14 in total

Review 1.  Renal sympathetic denervation: applications in hypertension and beyond.

Authors:  Michael Böhm; Dominik Linz; Daniel Urban; Felix Mahfoud; Christian Ukena
Journal:  Nat Rev Cardiol       Date:  2013-06-18       Impact factor: 32.419

2.  Renal denervation in the treatment of resistant arterial hypertension.

Authors:  Thomas Lambert; Wilhelm Schützenberger; Clemens Steinwender
Journal:  Wien Med Wochenschr       Date:  2014-11-14

Review 3.  Novel and nonpharmacologic approaches to cardio-protection in hypertension.

Authors:  Luca Donazzan; Felix Mahfoud; Dominik Linz; Sebastian Ewen; Christian Ukena; Michael Böhm
Journal:  Curr Hypertens Rep       Date:  2014-05       Impact factor: 5.369

4.  Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension.

Authors:  Abraham R Tzafriri; John H Keating; Peter M Markham; Anna-Maria Spognardi; James R L Stanley; Gee Wong; Brett G Zani; Debby Highsmith; Patrick O'Fallon; Kristine Fuimaono; Felix Mahfoud; Elazer R Edelman
Journal:  Sci Transl Med       Date:  2015-04-29       Impact factor: 17.956

Review 5.  [Interventional hypertension therapy in diabetes mellitus. Effects on blood pressure and glucose metabolism?].

Authors:  S Ewen; C Ukena; J Pöss; D Linz; M Böhm; F Mahfoud
Journal:  Herz       Date:  2014-05       Impact factor: 1.443

Review 6.  Renal denervation in the treatment of hypertension.

Authors:  Christian Ukena; Felix Mahfoud; Sebastian Ewen; Bodo Cremers; Ulrich Laufs; Michael Böhm
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

7.  Innervation patterns may limit response to endovascular renal denervation.

Authors:  Abraham R Tzafriri; Felix Mahfoud; John H Keating; Peter M Markham; Anna Spognardi; Gee Wong; Kristine Fuimaono; Michael Böhm; Elazer R Edelman
Journal:  J Am Coll Cardiol       Date:  2014-09-16       Impact factor: 24.094

8.  Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial.

Authors:  Murray D Esler; Michael Böhm; Horst Sievert; Christian L Rump; Roland E Schmieder; Henry Krum; Felix Mahfoud; Markus P Schlaich
Journal:  Eur Heart J       Date:  2014-06-04       Impact factor: 29.983

9.  Renal Sympathetic Denervation - A Review of Applications in Current Practice.

Authors:  Vikas Kapil; Ajay K Jain; Melvin D Lobo
Journal:  Interv Cardiol       Date:  2014-03

10.  Application in Hypertension of Renal Sympathetic Denervation - A Review.

Authors:  Dominik Linz; Felix Mahfoud; Sebastian Ewen; Stephan H Schirmer; Jan Reil; Christian Ukena; Michael Böhm
Journal:  Interv Cardiol       Date:  2013-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.